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Abstract: Pseudomonas aeruginosa is a major opportunistic pathogen in cystic fibrosis, wound and
nosocomial infections, posing a serious burden to public health, due to its antibiotic resistance.
The P. aeruginosa Pseudomonas Quinolone System (pqs) quorum sensing system, driven by the
activation of the transcriptional regulator, PqsR (MvfR) by alkylquinolone (AQ) signal molecules,
is a key player in the regulation of virulence and a potential target for the development of novel
antibacterial agents. In this study, we performed in silico docking analysis, coupled with screening
using a P. aeruginosa mCTX::PpqsA-lux chromosomal promoter fusion, to identify a series of new PqsR
antagonists. The hit compounds inhibited pyocyanin and alkylquinolone signal molecule production
in P. aeruginosa PAO1-L and PA14 strains. The inhibitor Ia, which showed the highest activity in PA14,
reduced biofilm formation in PAO1-L and PA14, increasing their sensitivity to tobramycin. Furthermore,
the hepatic and plasma stabilities for these compounds were determined in both rat and human in vitro
microsomal assays, to gain a further understanding of their therapeutic potential. This work has
uncovered a new class of P. aeruginosa PqsR antagonists with potential for hit to lead optimisation in
the search for quorum sensing inhibitors for future anti-infective drug discovery programs.
Keywords: Pseudomonas aeruginosa; PqsR; MvfR; Pseudomonas quinolone signal (PQS); alkylquinolone;
quorum sensing inhibition.
1. Introduction
Antimicrobial resistance has emerged as a global threat to public health, driven by complex
resistance mechanisms, a lack of new antibiotics and the misuse of clinically approved antibacterial
agents [1,2]. In recent years, a novel approach to combat antimicrobial resistance has begun to
attract attention, based on disarming bacterial virulence through the disruption of bacterial quorum
sensing (QS)-mediated communication systems. QS employs diffusible signals, sometimes called
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autoinducers (AIs), to control bacterial community behaviour by co-ordinating gene expression at the
population level, to promote pathogen survival and dissemination [3]. There are several approaches
to target QS from a drug discovery point of view and these include inhibition of the biosynthesis
of AIs, blocking the interaction of these signals with their receptors or through direct interference
with the signals, using enzymes or antibodies [4–6]. Among the organisms most clinically resistant to
antibiotics is Pseudomonas aeruginosa, an opportunistic gram-negative pathogen and leading cause of
diverse nosocomial infections, mainly in immunocompromised patients and individuals with cystic
fibrosis [7,8]. P. aeruginosa infections are commonly difficult to eradicate with conventional antibiotic
therapy, particularly when established as biofilms.
P.aeruginosa possesses three integrated quorum sensing circuits, known as las, rhl and the
Pseudomonas Quinolone System (pqs). The las and rhl systems are reliant on N-acylhomoserine
lactones (AHLs), whereas the pqs system utilises alkylquinolone (AQ) derived signal molecules [9].
The latter is regulated by the interaction between the transcriptional regulator, PqsR (MvfR), and
2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) or 2-heptyl-4-hydroxyquinoline (HHQ), which in turn
induce the transcription of the pqsABCDEphnAB operon, leading to the production of more AQs and
virulence factors, including pyocyanin as well as enhancing biofilm maturation [10,11]. It has been well
documented that interfering with PqsR activity disrupts biofilm development and increases sensitivity
to antibiotics, further validating its potential as a therapeutic target [12]. While the las and rhl systems
have been studied extensively, with many medicinal chemistry approaches described for developing
inhibitors that block binding of AHLs to their cognate receptors [13–17], the pqs system, as a therapeutic
target, has received less attention. Amongst the limited number of PqsR inhibitors are quinazolinone,
quinolinone, benzamide-benzimidazole and hydroxybenzamide derived molecules [18–22]. In this study,
we employed an in silico virtual screening method to search for novel PqsR inhibitors in a library of
quinoline-based molecules. Following that, the compounds were evaluated for their inhibitory activity,
using a suite of in vitro assays, to reveal a new generation of PqsR inhibitors with low micromolar potency.
The antagonists were then profiled for their metabolic stability in both humans and rats (plasma and
liver microsomes), to gain a better understanding of their therapeutic potential.
2. Results
2.1. In Silico Virtual Screening for PqsR Antagonists
We employed a virtual screening approach, to identify new inhibitors of PqsR from a library
of quinolone-derived molecules. The library was based on compounds, originally reported by
Ramírez-Prada et al. [23] as antiprotozoal agents, as they share a 7-chloro-4-aminoquinoline core
(Figure 1a) which closely resembles the native P. aeruginosa AQ co-inducer head group. The study
was performed using the crystal structure of the PqsR ligand binding domain, complexed with the
quinazolinone inhibitor, 3-NH2-7Cl-C9-QZN (abbreviated as QZN), reported by Ilangovan et al. [18]
(Figure 1b). We speculated that 7-chloro-4-aminoquinoline could form a suitable isostere for the head
group in the QZN antagonist, while the hydrophobic aromatic extension attached to the amino group
could replace the C9 alkyl chain in QZN (Figure 1c). Hence the Glide module of the Schrödinger Suite
was used to examine a total of 31 structures exploiting the extra-precision docking function [24].
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Figure 1. Structures of PqsR antagonists. (a) Chemical structures of quinolone-based compound
library; (b) Chemical structure of PqsR inhibitor 3-NH2-7-Cl-C9-QZN (QZN); (c) Overlay of a quinolone
derivative (yellow) and QZN inhibitor (blue).
Molecules 2018, 23, 257 3 of 15
The ligand binding pocket in PqsR consists of an inner pocket (B pocket) which accommodates
the quinoline head group and an elongated outer ‘A’ pocket, rich with hydrophobic residues that
interact with the aliphatic chain of the co-inducers. The docking study confirmed that the favorable
binding position for the quinoline library imitates the QZN inhibitor binding mode, where the
4-amino-quinoline core resides in the A pocket, while the aromatic tail extends to occupy the B pocket
(Figure 2c). Moreover, the chlorine atom at the 7-position of the quinoline adopts the same orientation
as the chlorine in the QZN and occupies the same small pocket formed by Thr265. The docking score,
represented as XP GScore (Table 1), suggested that the best potential candidates are those with an
unsubstituted ring C, while having a formyl or acetyl group on the pyrazoline ring B had no significant
effect. The best fit compounds were Ia, Ii, IIa and IIi (Table 1).
Table 1. Summary of docking scores and activity data for the library.
Molecules 2018, 22, x FOR PEER REVIEW  3 of 16 
 
Figure 1. Structures of PqsR antagonists. (a) Chemical structures of quinolone-based compound 
library; (b) Chemical structure of PqsR inhibitor 3-NH2-7-Cl-C9-QZN (QZN); (c) Overlay of a 
quinolone derivative (yellow) and QZN inhibitor (blue). 
The ligand binding pocket in PqsR consists of an inner pocket (B pocket) which accommodates 
the quinoline head group and an elongat d outer ‘A’ pocket, rich with hydrophobic residues that 
interact with the aliphatic chain of the co-inducers. The docking study confirmed that the favorable 
binding position for the quinoline library imitates the QZN inhibitor binding mode, where the 4-
amino-quinoline core resides in the A pocket, while the aromatic tail extends to occupy the B pocket 
(Figure 2c). M reover, the chlorine atom at the 7-position of the quinoline adopts the same orientation 
as the chlorine in the QZN and occupies the same small pocket formed by Thr265. The docking score, 
represented as XP GScore (Table 1), suggested that the best potential candidates are those with an 
unsubstituted ring C, hile having a formyl or acetyl group on the pyrazoline ring B had no 
significant effect. The best fit compounds were Ia, Ii, IIa and IIi (Table 1). 
Table 1. Summary of docking scores and activity data for the library. 
ID R1 R2 R3 
Glide 
XP Score 
PA14 Remaining 
activity % * 
PAO1-L 
Remaining 
activity % * 
IC50 PA14 
µM * 
IC50 
PAO1-L 
µM * 
Ia -H -Cl 4-H −9.856 18.7 ± 1.98 25.8 ± 1.17 2.3 ± 0.51  12.4 ± 1.79 
Ib -H -Cl 4-Me −5.179 78.4 ± 6.51 77.0 ± 2.25   
Ic -H -Cl 4-OMe −6.984 101.8 ± 11.67 100.3 ± 8.46   
Id -H -Cl 3,4,5-OMe −7.265 109.9 ± 14.98 130.3 ± 5.04   
Ie -H -Cl 4-F −5.24 70.4 ± 6.53 40.6 ± 3.71   
Ig -H -Cl 4-Br −6.34 94.8 ± 8.91 88.1 ± 6.05   
Ih -H -Cl 3,4-Methy- lenedioxy −4.056 85.8 ± 9.42 49.9 ± 12.01   
Ii -H -CF3 4-H −8.087 16.6 ± 1.3 15.6 ± 2.53 5.0 ± 0.82 5.1 ± 0.32 
Ij -H -CF3 4-Me −6.868 84.9 ± 8.17 93.7 ± 6.15   
Ik -H -CF3 4-OMe −4.867 99.7 ± 9.37 78.6 ± 5.75   
Il -H -CF3 3,4,5-OMe −2.219 106 ± 15.27 85.8 ± 2.39   
Im -H -CF3 4-F −7.118 74.9 ± 8.28 65.1 ± 4.89 -  
In -H -CF3 4-Cl −6.044 93.6 ± 4.45 61.8 ± 3.97   
Io -H -CF3 4-Br −6.390 80.6 ± 6.26 68.5 ± 3.43   
 
Ip -H -CF3 
3,4-Methy- 
lenedioxy −6.099 81.4 ± 9.36 84.3 ± 5.48   
IIa -Me -Cl 4-H −8.918 19.7 ± 1.9 31.6 ± 6.60 4.0 ± 1.62 1.6 ± 0.29 
IIb -Me -Cl 4-Me −5.0855 96.2 ± 4.34 59.5 ± 1.86   
IIc -Me -Cl 4-OMe −6.58033 114.9 ± 2.13 120.3 ± 8.28   
IId -Me -Cl 3,4,5-OMe −6.5015 110.4 ± 1.6 127.3 ± 9.69   
IIe -Me -Cl 4-F −7.1105 120.4 ± 1.59 82.6 ± 22.73   
IIf -Me -Cl 4-Cl −7.732 102.6 ± 4.91 90.2 ± 3.84   
IIg -Me -Cl 4-Br −4.9555 108.6 ± 2.79 63.7 ± 5.01   
IIh -Me -Cl 3,4-Methy- 
lenedioxy 
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ID R1 R2 R3
Glide
XP Score
PA14 Remaining
Activity % *
PAO1-L Remaining
Activity % *
IC50 PA14
µM *
IC50 PAO1-L
µM *
Ia -H -Cl 4-H −9.856 18.7 ± 1.98 25.8 ± 1.17 2.3 ± 0.51 12.4 ± 1.79
Ib -H -Cl 4-Me −5.179 78.4 ± 6.51 77.0 ± 2.25
Ic -H -Cl 4-OMe −6.984 101.8 ± 11.67 100.3 ± 8.46
Id -H -Cl 3,4,5-OMe −7.265 109.9 ± 14.98 130.3 ± 5.04
Ie -H -Cl 4-F −5.24 70.4 ± 6.53 40.6 ± 3.71
Ig -H -Cl 4-Br −6.34 94.8 ± 8.91 88.1 ± 6.05
Ih -H -Cl 3,4-Methy-lenedioxy −4.056 85.8 ± 9.42 49.9 ± 12.01
Ii -H -CF3 4-H −8.087 16.6 ± 1.3 15.6 ± 2.53 5.0 ± 0.82 5.1 ± 0.32
Ij -H -CF3 4-Me −6.868 84.9 ± 8.17 93.7 ± 6.15
Ik -H -CF3 4-OMe −4.867 99.7 ± 9.37 78.6 ± 5.75
Il -H -CF3 3,4,5-OMe −2.219 106 ± 1 27 85.8 ± 2.39
Im -H -CF3 4-F −7.118 74.9 ± 8.28 65.1 ± 4.89 -
In -H -CF3 4-Cl −6.044 93.6 ± 4.45 61.8 ± 3.97
Io -H -CF3 4-Br −6.390 80.6 ± 6.26 68.5 ± 3.43
Ip -H -CF3 3,4-Methy-len dioxy −6.099 81.4 ± 9.36 84.3 ± 5.48
IIa -Me -Cl 4-H −8.918 19.7 ± 1.9 31.6 ± 6.60 4.0 ± 1.62 1.6 ± 0.29
IIb -Me -Cl 4-Me −5.0855 96.2 ± 4.34 59.5 ± 1.86
IIc -Me -Cl 4-OMe −6.58033 114.9 ± 2.13 120.3 ± 8.28
IId -Me -Cl 3,4,5-OMe −6.5015 110.4 ± 1.6 127.3 ± 9.69
IIe -Me -Cl 4-F −7.1105 120.4 ± 1.59 82.6 ± 22.73
IIf -Me -Cl 4-Cl −7.732 102.6 ± 4.91 90.2 ± 3.84
IIg -Me -Cl 4-Br −4.9555 108.6 ± 2.79 63.7 ± 5.01
IIh -Me -Cl 3,4-Methy-lenedioxy −4.13 115.4 ± 6.02 65.8 ± 5.63
IIi -Me -CF3 4-H −8.5165 16.8 ± 1.01 26.1 ± 0.99 4.9 ± 0.30 5.14 ± 0.60
IIj -Me -CF3 4-Me −5.371 108.2 ± 6.05 97.3 ± 6.46
IIk -Me -CF3 4-OMe −6.799 118.1 ± 5.97 66.7 ± 0.42
IIl -Me -CF3 3,4,5-OMe −7.006 102.9 ± 4.84 86.1 ± 2.39
IIm -Me -CF3 4-F −3.578 99.9 ± 3.17 90.2 ± 4.40
IIn -Me -CF3 4-Cl −5.533 98.1 ± 11.38 97.8 ± 5.52
IIo -Me -CF3 4-Br −7.5535 95.6 ± 9.58 80.8 ± 5.06
IIp -Me -CF3 3,4-Methylenedioxy −6.8975 99.6 ± 4.09 71.6 ± 5.07
* Values are reported as Mean ± SD of n = 3 replicates.
Interestingly, chlorine substitution at the 7-position of the quinoline ring resulted in a slightly
higher GLIDE score, compared to the corresponding trifluoromethane-substituted compounds
(e.g., compare Ia and Ii). The docking positions for these ligands indicated the presence of pi-pi
interactions between ring C and Tyr258 as well as electrostatic contacts between the quinolone 4-amino
substituent and the side chains of Leu207, Leu208 and Arg209 (Figure 2a,b,d).
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concentration, and the activity was compared to a control of DMSO (0.1%) (Figure 3a). To be 
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(b) verlay of quinoline core in the inner pocket of PqsR; (c) Overlay of the entire library of compounds
in the PqsR binding domain; (d) Binding position for compound Ia.
.2. ole ell i se t
ter ine the ab lity of the quinolines to inhibit PqsR functionality, the P. aeruginosa biosensor
strains, PAO1-L and PA14, incorporating a chro TX::PpqsA-lux transcriptional fusion, were
used. These r port on th tivation of the pqsA promoter, regulated by PqsR [25]. PAO1-L and
PA14 w re chosen because th y ar genetically amenable and belong to the two major P. aeruginosa
genomic groups [26]. The quinolone compounds were incubated with the corresponding strain, and
luminescence and optical density readings were recorded to monitor the effect of the quinolines on PqsR
activity and bacterial growth, respectively. The compounds were screened at 10 µM concentration,
and the activity was compared to a control of DMSO (0.1%) (Figure 3a). To be considered a hit,
a threshold of at least 50% inhibition of the test compound, relative to the negative control had to
be reached, without affecting bacterial growth. The library showed variable activity towards the
reporters (Table 1, Figure 3a) and a total of four inhibitors (Ia, Ii, IIa and Iii) were identified with
strong PqsR inhibitory activity for both P. aeruginosa strains, without interfering with bacterial growth
(Figure 3a,d,e). Concentration-response experiments were then carried out to determine the IC50
values (Figure 3b,c), which are summarised in Table 1.
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Ii and IIi had the same PqsR inhibitory activity against both strains (IC50 5 µM), while compound 
Ia was the most active inhibitor of PA14 (IC50 2.2 µM), but exhibited only modest activity against 
PAO1-L. In contrast, IIa was the most active PqsR antagonist for PAO1-L (IC50 1.5 µM), compared 
with PA14 (IC50 of 3.7 µM). 
2.3. Impact of PqsR Antagonists on Pyocyanin Production 
Figure 3. Whole bacterial cell-based P. aeruginosa compound screen for both PqsR and growth
inhibition (a) Activity against PA14 (green) and PAO1-L (purple) PpqsA-lux reporter strains at 10 µM test
compound; (b) and (c) Dose-response curves for active compounds against PA14 (b) and PAO1-L (c);
(d) and (e) growth curves for PA14 (d) and PAO1-L (e) in the presence of compound or DMSO control.
Ii and IIi had the same PqsR inhibitory activity against both strains (IC50 5 µM), while compound
Ia was the most active inhibitor of PA14 (IC50 2.2 µM), but exhibited only modest activity against
PAO1-L. In contrast, IIa was the most active PqsR antagonist for PAO1-L (IC50 1.5 µM), compared
with PA14 (IC50 of 3.7 µM).
2.3. Impact of PqsR Antagonists on Pyocyanin Production
Pyocyanin is a blue redox-active toxin, produced by P. aeruginosa and strongly-controlled by
PqsR via the regulation of pqsE expression [11,27,28]. Pyocyanin is essential for the pathogenicity of
P. aeruginosa in lung infections [29]. The effect of the PqsR inhibitors on pyocyanin production by
PA14 and PAO1-L strains, when grown in the presence or absence of the inhibitors, was investigated
(Figure 4). All the compounds tested demonstrated significant inhibition when used at a concentration
equivalent to three-fold their IC50 values. Compound Ia had the strongest effect on pyocyanin
production in both strains, followed by Ii and IIi, while IIa had the weakest effect, with just over 25%
reduction, despite its low micromolar potency in the reporter assay.
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2.4. Impact of Hit Compounds on Alkylquinolone Production
P. aeruginosa produces a broad rang of alkylquinolones, v a PqsABCDE, some of which (e.g., PQS
and HHQ) act as quorum sensing signal molecules, while others (e.g., 2-heptyl-4-hydroxyquinoline
N-oxide; HQNO) do no [11,30]. HQNO, c n protect Staphylococcus aureu fr m vancomycin [31] and
contributes to the environmental competitiveness of P. aeruginosa, through its activity as a potent
inhibitor of the cytochrome bc1 complex [32]. AQ biosynthesis is tightly-r gulat d by PqsR, hence
inhibition of this transcriptional regulator is reflected by a reduction in AQ production that can be
used as a readout for PqsR inactivation. LC-MS/MS w s used to quantify the major AQs HHQ, PQS
and HQNO after incubation of the P. aeruginosa strains with the hit compounds, for 16 h. The assay
was performed using both PAO1-L and PA14 strains which were treated with PqsR antagonists at
concentrations three-fold higher than their IC50 values. The results obtained depended on the inhibitor
and strain tested (Figure 5). Compound Ii showed the greatest inhibition of AQ production in PAO1-L;
however, this was not observed for PA14. Furthermore, IIa had only a moderate effect, whereas Ia
maintained a strongly-inhibited AQ production for both strains, in agreement with the pyocyanin data
(compare Figures 4 and 5).Molecules 2018, 22, x FOR PEER REVIEW  7 of 16 
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2.5. Effect of PqsR Antagonists on Biofilms
One of the clinical challenges of P. aeruginosa infections is the difficulty associated with the effective
treatment of biofilms due to their high resistance to antibiotics. The pqs system has been shown to
regulate a number of genes required for biofilm development [27] and hence, inactivation of this system
through antagonism of PqsR is a promising approach, as it can sensitize biofilms to conventional
antibiotics [33]. The effect of Ia, with or without tobramycin, on PA14 and PAO1-L biofilms grown on
glass coverslips, was determined. Ia was the compound of choice, as it demonstrated relatively strong
inhibitory activity in each of the assays used in this study. The experiment was performed using green
fluorescent labelled (GFP)-labelled PAO1-L and PA14 strains, grown under four different conditions:
(i) no treatment (control); (ii) compound Ia at 8 µM in PA14 and 34 µM in PAO1-L (concentrations
equal to 3× IC50); (iii) tobramycin at 100 µg/mL; (iv) Ia and tobramycin, at the same concentrations as
(ii) and (iii).
Figure 6 shows that exposure to Ia had a substantial effect on biofilm development for both
PAO1-L and PA14, reducing biomass with little impact on cell viability, as measured using propidium
iodide (red bars) (Figure 6a,b,f,g,e,j). Treatment with tobramycin significantly reduced biofilm biomass,
increasing the proportion of dead bacterial cells substantially (Figure 6c,h,e,j). Most importantly, the
combined treatments had a synergistic effect with near complete biofilm eradication (Figure 6d,i,e,j).
These data further validate the pqs system in Pseudomonas as a target that can aid the effectiveness of
antibiotic treatment for biofilm-centred infections.Molecules 2018, 22, x FOR PEER REVIEW  8 of 16 
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Figure 6. Effect of Ia on P. aeruginosa biofilms. (a) Untreated GFP-labelled PA14 biofilm; (b) GFP-
labelled PA14 biofilm grown with Ia at 8 µM; (c) GFP-labelled PA14 biofilm, treated with 100 µg/mL
tobramycin for 4 h after 16 h of growth; (d) GFP-labelled PA14 biofilm grown with 8 µM Ia and treated
with 100 µg/mL tobramycin for 4 h after 16 h of growth; (e) Biomass quantitation of PA14 biofilms;
(f) Untreated GFP-labelled PAO1-L biofilm; (g) GFP-labelled PAO -L biofilm grown with Ia at 34 µM;
(h) GFP-labelled PAO1-L biofilm, treated with 100 µg/mL tobramycin for 4 h after 16 h of growth;
(i) GFP-labelled PAO1-L biofilm grown with 34 µM Ia and treated with 100 µg/mL tobramycin for
4 h after 16 h of incubation; (j) Biomass quantitation of PAO1-L biofilms. Dead cells and extracellular
DNA were stained with propidium iodide (PI). Three-dimensional (3D) sections and cross sections are
shown. Scale bars represent 100 µm.
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2.6. Determination of the Plasma and Hepatic Stability of Selected Quinolone Inhibitors
To gain a greater understanding of the potential of the quinolone inhibitors to progress towards
a hit to lead optimization process, in vitro plasma and hepatic stability assays were performed.
The results obtained (Table 2) show that each of the selected compounds possesses a high degree of
stability in rat plasma and to a less extent in human plasma, where the half-lives varied, with the most
stable compound being IIa (Table 2). Microsomal stability usually represents Phase 1 metabolism of a
drug, although it does not incorporate factors such as protein binding, which can lead to enhanced
in vivo stability. The majority of the compounds tested demonstrated moderate to high intrinsic
clearance with relatively short half-lives of <30 min in both human and rat microsomes. Inhibitors Ia
and Iii showed the greatest plasma stability.
Table 2. Summary of plasma and microsomal stability of PqsR inhibitors.
Plasma Stability Microsomal Stability
Rat Human Rat Human
Compound ID t1/2(min)
t 1/2
(min)
Clint *
(µL/min/mg)
t1/2
(min)
Clint
(µL/min/mg)
t1/2
(min)
Ia >240 132.2 122.5 11.5 60.3 23.3
Ii >240 69.1 54.1 25.7 80.7 17.2
IIa >240 73.8 87.8 15.8 73.0 19.0
IIi >240 157.1 65.7 21.1 72.9 19.0
* Clint: intrinsic clearance.
3. Discussion
Antimicrobial resistance has become a global challenge with very slow progress in the
development of novel therapeutics [2]. As a multi-antibiotic resistant Gram-negative pathogen,
P. aeruginosa constitutes a major clinical threat [34,35]. There is a growing body of literature describing
several approaches to attenuate bacterial virulence through interference with the expression or activity
of virulence factors [36]. Despite some reports on the emergence of resistance to these agents,
these approaches are becoming more popular for treating bacterial infections, as they pose less
selective pressure on the bacterial pathogen [37,38]. Disruption of QS can provide an alternative
approach to conventional antibacterial therapy, as it targets bacterial virulence, rather than bacterial
viability [4,39–41]. The pqs system plays a critical role in regulating virulence and biofilm development,
through the transcriptional regulator, PqsR [42]. In this study, we employed a molecular modelling
approach using the Schrödinger Suite [24] to assess a series of 4-amino-quinoline-based compounds
with three sites for amenable structural modifications. To our knowledge, this is the first report
describing the use of this in silico approach to search for PqsR inhibitors. Our docking results
highlighted four compounds with the potential to bind to PqsR, adopting similar conformations
to the reported QZN inhibitor [15]. The interactions within the PqsR ligand-binding site and Ia,
Ii, Ia, Ii were mainly dominated by a hydrophobic pi-pi interaction with Tyr258 and electrostatic
interactions between the 4-amino and the side chains of Leu207, Leu208 and Arg209. Moreover, the
chlorine and trifluoromethane groups at the 7-position adopted similar orientations towards Thr265,
in agreement with the previously-reported binding orientation for QZN [18]. It is noteworthy that
substitution at the para-position was not tolerated and resulted in a substantial reduction in the
GLIDE docking score, as this may cause a change of conformation to the phenyl ring, affecting the pi-pi
interaction with Tyr258. To confirm that these results can be translated to P. aeruginosa cells, we used
biosensor reporter strains, in which a chromosomal transcriptional fusion of PpqsA-lux was introduced.
This responds to endogenous AQ production by emitting light. In the presence of an antagonist,
bioluminescence is reduced, providing a simple read-out [25]. Compounds active in this reporter
assay may either be inhibitors of PqsR or of AQ biosynthetic enzymes. The results obtained with
the quinolines confirmed that compounds (Ia, Ii, Ia, Ii) are active in both P. aeruginosa strains tested
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at low micromolar concentrations. In addition, there were some other hits with selective activity
against one of the strains. These results highlight the importance of including multiple strains to
validate the activity of an inhibitor, as its potency may vary in a strain-dependent manner. Interestingly,
all reported PqsR inhibitors to date were examined using a single P. aeruginosa strain, highlighting
the need for these compounds to be tested in different strains before further optimisation is carried
out [19,22,43,44]. In fact, it is crucial that anti-Pseudomonas agents undergo a rigid assessment of their
activity in representative strains and fresh clinical isolates before they can be considered candidates,
as this would greatly reduce the chances of expensive failure at the clinical stage, due to lack of
potency [26]. The reasons for such differences are not clear, as yet, but may be attributable to different
cell envelope permeabilities, active efflux pumps or a secondary mode of action at a different target [45].
In the present study, only compounds that showed consistent potency in both PA14 and PAO1-L were
further assessed using phenotypic analysis.
A pyocyanin quantitation assay upon treatment with the compounds revealed that Ia was the
most effective at reducing phenazine production, followed by Ii. Surprisingly, IIa reduced pyocyanin
modestly, despite being the most potent inhibitor in the bioreporter assay. In agreement with our
findings for pyocyanin, Ia was the most potent inhibitor of AQ production, followed by IIa, the effect
of which was substantial for PAO1-L. The remaining inhibitors showed only modest, variable effects on
AQ production. Collectively, the inhibitory activity of the compounds, alongside the in silico modelling,
is consistent with PqsR as their target. However, the PpqsA-lux reporter assay used does not distinguish
between inhibitors of PqsR and AQ biosynthetic enzymes, and further work will be required to
confirm that PqsR is their direct target [19,22,43,44]. Based on the results obtained, Ia was evaluated
for anti-biofilm activity. Ia disrupted biofilm development and reduced biomass, without affecting
bacterial viability. Furthermore, Ia sensitized the biofilm to tobramycin, as reflected by an improved
potency in killing both PAO1-L and PA14 biofilms, a finding that supports previous reports that
inhibition of pqs signalling disrupts biofilm integrity and its sensitivity to antibiotic treatment [33,46].
Before progressing a hit to lead optimisation process, it is important to determine the stability
of the most active hits in plasma and hepatic microsome assays. The latter experiments are essential
for predicting the metabolic stability of a putative drug and aid medicinal chemistry decisions [47,48].
The stability study showed that these inhibitors present a reasonable level of plasma stability; however,
the intrinsic clearance values in hepatic microsomes were elevated and their half-lives were relatively
short (less than 30 min). Thus, further chemical refinement to improve hepatic stability should be
considered if these molecules are to be pursued as leads. Nevertheless, we have introduced a new
class of low micromolar putative PqsR inhibitors that constitute a starting point for further medicinal
chemistry studies aiming at optimising their potency and physicochemical properties, to generate
clinically useful therapeutic agents particularly as adjuvants for antibiotics in the context of P. aeruginosa
biofilm-centred infections.
4. Materials and Methods
4.1. Molecular Docking
4.1.1. Preparation of Protein and Receptor Grid Generation
The X-ray crystal structure of PqsR ligand binding domain in complex with the QZN inhibitor
(PDB ID: 4JVI) was used as a protein template. The protein was prepared using the protein preparation
wizard (Small-Molecule Drug Discovery Suite 2017-4, Schrödinger, LLC, New York, NY, USA), where
hydrogen atoms were added, water molecules were removed and the correct bond order was assigned
to the amino acid residues. Afterwards, a receptor grid generation was performed, based on defined
residues around the ligand binding sites: (Ala102, Pro129, Ile149, Thr166, Ala 168, Val 170, Ile186,
Ile189, Gln194, Ser196, Leu196, Leu197, Leu207, Leu208, Pro210, Val211, Trp234, Gly235, Pro238,
Ser255). The inner grid box was set to 10 Å, while the outer box was 20 Å.
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4.1.2. Ligand Preparation
The chemical structures of the inhibitors were sketched using ChemDraw (Version 16.0.1.4,
PerkinElmer informatics) via an SDF file. LigPrep module (Small-Molecule Drug Discovery Suite
2017-4, Schrödinger, LLC, New York, NY, USA) was then used for final preparation of ligands into their
lowest energy 3D conformations. The partial atomic charges were assigned to the molecular structures,
using the 2005 implementation of the OPLS-AA force field. These energy-minimized structures were
used for Glide) docking.
4.1.3. Molecular Docking
The “Extra Precision” (XP) mode of Glide docking (Small-Molecule Drug Discovery Suite 2017-4,
Schrödinger, LLC, New York, NY, USA) was used to perform all docking calculations, using the
OPLS-AA 2005 force field. The scale factor of 1.0 for van der Waals radii was applied to atoms of
protein with absolute partial charges of less than or equal to 0.25. The number of position per ligand
was set to five, after energy minimization. The best docked structures were chosen using an XP Glide
Score (XP Gscore) function as well as visual observations.
4.2. Bacterial strains and growth conditions
The P. aeruginosa strains and plasmids used in this study are shown in Table 3. Bacteria were
grown in lysogeny broth (LB) at 37 ◦C, unless stated otherwise. Where required, tetracycline (Tc) was
added to the media at 125 µg/mL, to select for recombinants. Synthetic alkylquinolones were added at
the concentrations indicated.
Table 3. Bacterial strains and plasmids used in this study.
Strain or Plasmid Relevant Characteristics Reference or Origin
P. aeruginosa
PAO1-L Wild type PAO1, Lausanne subline. B. Holloway, via D. Haas
PAO1-L mCTX::PpqsA-lux PAO1-L with chromosomal mini-CTX::PpqsA-lux insertion; TcR This study
PA14 Wild type UCBPP-PA14 [49]
PA14 mCTX::PpqsA-lux PA14 with chromosomal mini-CTX::PpqsA-lux insertion; TcR This study
Plasmids
mini-CTX::PpqsA-lux R6K-based mini-CTX suicide plasmid for the chromosomal insertion
of a PpqsA-lux transcriptional reporter fusion; TcR
[50]
pMMG pME6032∆lacI constitutively expressing GFP from the Ptac promoter [51]
4.3. Biosensor Reporter Assay
Strains PA14 mCTX::PpqsA-lux and PAO1-L mCTX::PpqsA-lux were constructed using plasmid
mini-CTX::PpqsA-lux, as previously described [50], and the assay was performed according to a
published protocol [52]. For screening, the compounds were tested at a concentration of 10 µM,
which was prepared from a 10 mM stock, in DMSO.
4.4. Pyocyanin Quantification
The experiment was performed following a published protocol with minor modifications [53].
P. aeruginosa strains were cultured into 5 mL fresh medium overnight. Compounds were assayed at
3× IC50s, for 16 h, at 37 ◦C (Kuhner LT W Shaker, Adolf Kühner AG, Basel, Switzerland). Cells were
centrifuged at 10,000 RCF for 10 min (Allegra 64R centrifuge, Beckman Coulter, High Wycombe, UK)
and the supernatant was transferred to 15 mL falcon tubes with a HSW 10 mL Soft-Ject Syringe and a
0.22 µM Sartorius syringe-driven filter (Fisher Brand, Loughborough, UK). Pyocyanin pigment was
extracted into chloroform by mixing 7.5 mL of supernatant with 4.5 mL of chloroform. Pyocyanin was
further extracted into 1.5 mL of 0.2 M HCL, which gave a pink/red solution, and the absorbance was
measured at 520 nm.
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4.5. LCMS-MS Alkyl Quinoline Quantification
For each test sample, 100 µL of sterile filtered supernatant (the same preparation as for pyocyanin)
was spiked with 10 µL of an internal standard solution (10 µM d4-PQS in MeOH), and diluted with
water, to a total volume of 500 µL. Samples were then extracted three times with an 0.5 mL aliquot
of ethyl acetate, vortex mixing the aqueous/organic mix for 2 min, then removing the organic phase
once the layers had successfully partitioned. For each sample, the combined organic extracts were
dried under vacuum and re-dissolved in 100 µL MeOH prior to analysis. For the LC-MS/MS analysis
of supernatant extracts, the chromatography was achieved using a Shimadzu series 10AD VP LC
system (Columbia, MD, USA). The LC column, maintained at 40 ◦C, was a Phenomenex Gemini C18
(3.0 µm, 100 × 3.0 mm) (Macclesfield, Cheshire, UK) with an appropriate guard column. Mobile phase
A was 0.1% (v/v) formic acid in water containing 2 mM 2-picolinic acid, and mobile phase B 0.1% (v/v)
formic acid in methanol. The flow rate throughout the chromatographic separation was 450 µL/min.
After an injection of a 2 µL/sample, a binary gradient, beginning initially at 30% B, increased linearly
to 99% B over 5 min. The composition remained at 99% B for 3 min, decreased to 30% B over 1 min,
and stayed at this composition for 4 min, to allow for column equilibration. The MS system used for
analyte detection was an Applied Biosystems Qtrap 4000 hybrid triple-quadrupole linear ion trap
mass spectrometer (Foster City, CA, USA), equipped with an electrospray ionisation (ESI) interface.
Instrument control, data collection and analysis were conducted using Analyst software (Foster City,
CA, USA). The MS analysis was achieved with positive electrospray (+ES) multiple reaction monitoring
(MRM) screening of the LC eluent for specific AQ analytes. Where chromatographic peaks for HHQ,
HQNO and PQS were detected, a peak area was determined, and analyte peak area/internal standard
peak area calculated.
4.6. Biofilms
Biofilms were cultivated on borosilicate glass coverslips in petri dishes. P. aeruginosa strains,
PAO1-L and PA14, were labelled by transformation with plasmid pMMG, which constitutively
expresses GFP from the Ptac promoter [51]. Labelled strains were grown at 37 ◦C, for 16 h, in 2 mL
RPMI-1640 (Lonza, Slough, UK), supplemented with 20 mM D-glucose (Sigma–Aldrich, Dorset, UK)
and 2 µM FeCl3 (Sigma–Aldrich, Dorset, UK). Cultures were diluted 1:100 in fresh medium and
allowed to grow for a further 4 h, or until an OD600 of 0.5 was reached. The mid-logarithmic cultures
were diluted to an OD600 of 0.01 in 25 mL RPMI, supplemented with glucose and FeCl3, and inoculated
into petri dishes containing UV sterilised borosilicate glass coverslips (22 × 22 mm, thickness no1)
(VWR, Lutterworth, UK). Bacterial cells were seeded at 37 ◦C under static conditions for 1.5 h, and
compound Ia was added to the culture at a concentration of 34 µM for P. aeruginosa PAO1-L and
8 µM for PA14 before dishes were moved to a shaker at 60 rpm and 37 ◦C for 15 h to form mature
biofilms. Tobramycin and propidium iodide were added to the 15 h-old cultures at concentrations of
100 µg/mL and 2 µM, respectively, followed by further incubation for 4 h. Coverslips were examined
under a Laser Scanning Fluorescent Microscope (LSM2, Zeiss, Oberkochen, Germany). Biofilms
were visualised using egfp mode at an excitation wavelength of 488nm. Imaging was carried out
using Zen 2011 imaging software (Zeiss, Oberkochen, Germany). A total of 5 Z-stacked images were
collected per coverslip. Sampling was conducted at random from the central portion of each coverslip.
Biomass was calculated using Image J (NIH, Bethesda, MD, USA) and Comstat 2.1. Software package
(www.comstat.dk, lyngby, Denmark) [54].
4.7. Determination of Plasma Stablity
Dilutions of a 10 mM test compound DMSO stock solution were prepared so that the final DMSO
concentration was 1% v/v and the final test compound concentration tested was 1 µM. Following
the addition of the test compound to plasma, the samples were pre-incubated for 10 min prior to
the start of the incubation by the addition of the test compound. The test compound was incubated
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(n = 2; 1 µM final concentration) at 37 ◦C with plasma for up to 2 h. Aliquots were sampled at several
time points and mixed with acetonitrile (containing internal standard) to terminate the reaction and
precipitate the proteins. All the samples were mixed, centrifuged and the supernatants analysed by
UPLC-MSMS. Parent disappearance and half-life (t 1/2) values were determined from the slope of the
parent depletion curve. Control compounds (imidapril, enalapril, tenofovir and/or propantheline),
were respectively included.
4.8. Determination of Hepatic Stability
Dilutions of a 1 mM test compound DMSO stock solution were prepared in buffer (typically
0.01 M phosphate buffered saline (pH 7.4) so that the final DMSO concentration was 0.1% v/v and the
final test compound concentration tested was 1 µM. Following addition of protein (0.5 mg/mL final)
and NADPH, the samples were pre-incubated for 10 min prior to the start of the incubation by the
addition of test compound. The test compounds were then incubated (n = 2; 1 µM final concentration)
at 37 ◦C with tissue microsomes. Aliquots were sampled at several time points and mixed with
acetonitrile (containing internal standard) to terminate the reaction and precipitate the proteins. All the
samples were mixed, centrifuged and the supernatants analysed by UPLC-MS/MS. The intrinsic
clearance (Clint) and half-life (t 1/2) values were determined from the slope of the parent depletion
curve. Control compounds for low, moderate and high intrinsic clearance, respectively, for both human
and rat microsomes, were included.
4.9. Data Analysis and Figure Preparation
Sigmoidal dose-response curves and the representation of all data were prepared using GraphPad
Prism 7.
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